Would you consider using an anthracycline-based regimen again for a breast cancer patient who previously received doxorubicin 10 years prior?
The patient was previously treated with TAC x 6 (cumulative Adriamycin dose of 300 mg/m2) for a triple negative breast cancer. Would you consider incorporating carboplatin to increase pCR rate with anthracyclines likely containdicated?
How would you weigh using Docetaxel/Cyclophosphamide option versus carboplatin with taxane?
Answer from: Medical Oncologist at Academic Institution
I would not re-treat with an anthracycline for several reasons. She is at higher risk of heart failure (HF) by virtue of the prior exposure to anthracyclines, and you couldn't get in standard course of anthracyclines because of quickly exceeding the 450 mg/m2 limit where the risks HF increase drama...
Sign in or Register to read more